Clinical Trials Study
Copyright ©The Author(s) 2025.
World J Diabetes. Jul 15, 2025; 16(7): 105219
Published online Jul 15, 2025. doi: 10.4239/wjd.v16.i7.105219
Table 1 Comparison of the baseline characteristics, mean ± SD
Variables
Con group (n = 20, ITT analysis)
Con group (n = 17, PP analysis)
XQG group (n = 20, ITT or PP analysis)
Sex (male/female)8/127/105/15
Age (year)51.10 ± 10.8852.65 ± 10.5251.65 ± 12.56
DD (month)52.25 ± 53.3256.18 ± 56.3933.55 ± 33.35
BMI (kg/m2)23.15 ± 3.0923.06 ± 3.2423.64 ± 4.08
SBP (mmHg)120.85 ± 12.71120.18 ± 13.50119.30 ± 15.20
DBP (mmHg)77.50 ± 8.6876.65 ± 8.9379.05 ± 8.74
FPG (mmol/L)6.48 ± 0.476.48 ± 0.496.26 ± 0.47
2hPG (mmol/L)10.20 ± 3.3410.42 ± 3.519.71 ± 2.03
HbA1c (%)5.97 ± 0.485.95 ± 0.315.92 ± 0.33
FINS (μIU/mL)9.23 ± 4.909.52 ± 5.2715.07 ± 12.46
HOMA-IR2.67 ± 1.472.76 ± 1.594.15 ± 3.28
ALT (TU/L)22.15 ± 9.9023.22 ± 10.2226.76 ± 17.52
AST (U/L)21.83 ± 4.4322.29 ± 4.6224.99 ± 7.44
BUN (mg/dL)5.03 ± 1.205.19 ± 1.225.61 ± 0.96
Cr (mg/dL)61.50 ± 10.6061.14 ± 10.8564.46 ± 15.71